Submissions open for Dr. Harvey Yamamoto Award

Article

The graduating student with a winning essay will earn a $1,000 cash prize and a one-year membership to the American Optometric Society.

 

Submissions are now being accepted for the 3rd Annual Dr. Harvey Yamamoto Award, the American Optometric Society (AOS) announced.

A $1,000 cash prize will be awarded to a graduating optometry student, based on an original essay submission on the topic, “How can social media be used in the optometric practice to improve patient care and outcomes?” The winner will be presented with his or her check, plaque, and one-year paid membership in the AOS at the organization’s annual CE meeting, April 12-14.

For rules and additional information, contact Joel Rothschild at 805/768-4267 or Joel@optometricsociety.org.

 

Read more articles in this week's News Flash.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
© 2025 MJH Life Sciences

All rights reserved.